The medication generally provides supportive therapeutic benefit used in situations involving certain distressing symptoms, specifically those where difficulty breathing and mucus accumulation may be present. It is relevant in clinical settings marked by temporary physiological imbalance caused by respiratory congestion. This combination is considered relevant for managing symptoms associated with Bronchial Asthma, Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), and Respiratory Tract Infections (RTI).

Relief for Constricted Airways and Wheezing

This domain helps address symptom clusters that interfere with daily comfort, such as wheezing, chest tightness, and shortness of breath, in conditions characterized by periods of heightened symptoms. The medication offers symptomatic relief that helps patients cope more steadily with difficult episodes, and contributes to improved comfort during periods of heightened symptoms.

Management of Thick Mucus and Productive Cough

This domain addresses symptoms that create noticeable physiological strain, specifically tenacious mucus and viscous phlegm driving a productive cough in conditions involving inflammatory or irritative processes. This is relevant for managing symptoms that interfere with daily comfort, and may assist with easing the symptom load associated with tenacious secretions.

Quick Fact: Symptomatic Relief Domains
Symptom Axes	Used for managing Airway Constriction and Mucus Congestion
Primary Benefit	Provides support that helps ease the overall symptom burden
Use Context	Applied in acute exacerbations and episodic manifestations

Regulatory References

1. Levosalbutamol, Ambroxol, and Guaiphenesin Syrup - EFDA

Eligibility Map: Official Regulatory Information

The eligibility profile for Levolin PLUS (Levosalbutamol, Ambroxol, Guaifenesin combination) is defined by mandatory exclusions and cautions based on patient characteristics, as stated in government-approved labeling.

Eligibility Classification	Population Group or Condition
Contraindicated (Must Not Use)	Known hypersensitivity to any component; gastric ulceration; pre-existing ischaemic heart disease or severe cardiac disease; thyrotoxicosis; use for threatened abortion [Torrent Pharmaceuticals, EFDA].
Not Recommended	Children under 6 years of age (due to insufficient data); pregnancy (especially the first trimester); and lactation (breastfeeding) [Truemeds, EFDA].
Use with Caution	Patients with diabetes mellitus, hypertension, cardiac arrhythmias, convulsive disorders (e.g., seizures), or hyperthyroidism [EFDA, Torrent Pharmaceuticals].
Conditional Use	Patients with severe renal impairment or severe hepatic impairment, as reduced organ clearance may lead to accumulation of components or metabolites [Torrent Pharmaceuticals].

These eligibility domains reflect the regulatory mandate to restrict the medicine's use in individuals whose pre-existing conditions or physiological state may increase risk due to the systemic effects of the bronchodilator component or the clearance of the expectorant/mucolytic agents.

The official regulatory profile for Levolin PLUS documents specific interaction patterns concerning its active components: Levosalbutamol, Ambroxol, and Guaifenesin.

Drug–Drug Interactions

Co-administration with β-blockers is generally not recommended because these agents may antagonize the bronchodilatory action of the Levosalbutamol component, risking the precipitation of severe bronchospasm. Due to the sympathomimetic action of Levosalbutamol, combining the drug with Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants (TCAs) may potentiate cardiovascular effects; therefore, the drug must not be administered within 14 days of stopping MAOIs. The combination of the Ambroxol component with cough suppressants/antitussives is not recommended as this may inhibit the cough reflex, potentially leading to the accumulation of sputum.

Exposure and Clearance Alterations

• Certain non-potassium-sparing diuretics may cause an additive electrolyte effect, which can worsen the hypokalemia associated with the β₂-agonist component.
• The Levosalbutamol component is documented to cause a decrease in serum Digoxin levels.
• Ambroxol is associated with a resulting increase in concentrations of certain antibiotics (e.g., Amoxicillin, Erythromycin) in lung tissues.
• Serious hepatic or renal impairment is officially noted as a condition that alters the clearance of Ambroxol, leading to an expectation of reduced clearance or metabolite accumulation.
• The Guaifenesin component may interfere with laboratory tests for urinary 5-HIAA and VMA, potentially yielding false test results.

The drug's function is achieved through a triple-action pharmacological mechanism that modulates the physiological factors that contribute to airway constriction and mucus stagnation simultaneously.

The mechanism begins with Levosalbutamol acting as a selective agonist on mathbfbeta2-adrenergic receptors in bronchial smooth muscle cells. This binding initiates the cAMP/PKA cascade, which lowers the concentration of intracellular ionic calcium ( Ca^2+) required for contraction. The resulting physiological consequence is the relaxation of the tight muscle bands, which mechanically increases the internal diameter of the air passages and directly increases the potential for air passage.

The dual action on secretions is managed by Ambroxol and Guaifenesin. Ambroxol acts as a secretolytic agent, disrupting the structure of mucopolysaccharide fibres and promoting pulmonary surfactant release to lower the mucus's viscosity and stickiness. Concurrently, Guaifenesin activates a gastric vagal reflex, stimulating the production of water-rich fluid in the airways to hydrate secretions, facilitating mucociliary transport. This pharmacological synergy ensures the bronchodilator mechanism of Levosalbutamol supports the mechanical clearance of the fluid-modulated secretions.

How to Use Levolin PLUS

The instructions for administering Levolin PLUS (Levosalbutamol, Ambroxol, and Guaifenesin) follow a defined protocol for route, dosage, and frequency.

Official Administration Guidelines

Levolin PLUS is formulated as an oral syrup, making oral administration the only approved route. The preparation steps are essential for proper dosing.

Age Group	Typical Single Dose Volume	Frequency and Limit
Adults and Adolescents (12 years)	5 mL to 10 mL	Two to three times daily
Children (6 to 12 years)	5 mL	Two to three times daily
Children (2 to 5 years)	2.5 mL	Two to three times daily

Administration Requirements and Constraints

• Preparation: The container must be shaken well before use to ensure the uniform distribution of the active ingredients.
• Measurement: Accurate measurement of the prescribed dose volume (e.g., 5 mL or 10 mL) must be achieved using a provided or suitable measuring device.
• Timing: The syrup is generally taken in divided doses throughout the day (e.g., twice or thrice daily) and may be administered with or without food.
• Dose Limit: Labeling emphasizes that the recommended dose must not be exceeded, and typically, not more than four doses should be given in any 24-hour period.
• Population Note: Caution and potential dose modification (e.g., increased dose interval) may be required for patients with severe renal impairment. Use in children under two years is generally restricted or not recommended without specific professional direction.

These instructions constitute the standardized protocol for the medication's use.

Research Evidence / Overview of Studies for Levolin PLUS

This overview describes the scope and structure of the clinical research conducted for the Levosalbutamol, Ambroxol, and Guaifenesin combination, focusing solely on the types of evidence available from authoritative sources.

---

Evidence for Symptom Management of Productive Cough and Airway Tightness

Research for this specific fixed-dose combination has primarily explored its use in conditions characterized by fluctuating or episodic manifestations. The available evidence typically stems from real-world settings after initial marketing authorization, known as Phase IV Clinical Trials and Post-Marketing Surveillance (PMS) Studies. This type of research was evaluated in observational settings and is relevant in evidence describing how symptoms are measured in routine clinical practice.

Study Designs and Measured Outcomes

Research examined the combination in studies conducted during periods of increased symptom activity. The main focus was the evaluation of changes in Cough Severity Scores (CSS), which are standardized, multi-point scales used in research exploring how symptoms change over time. Research describes patterns related to how symptoms were reported by patients during the study period. Evidence is limited, and the body of research includes few large-scale, randomized, double-blind trials for the specific combination product.

---

Follow-up Duration and Understanding of Long-Term Use

As studies explored short-term symptom changes, the follow-up durations were limited. Research primarily examined short-term symptom changes and reflected observation periods lasting only for the duration of the typical acute treatment course, usually not exceeding one week. Because of the short duration of the studies, long-term effects are not fully established, and the certainty remains low regarding outcomes beyond the acute phase of treatment.

---

Evidence in Specific Patient Groups

The combination was studied for use in a wide range of patients. Research examined both Adults and Pediatric populations (including infants and older children). The evidence base includes a significant focus on the pediatric population, which was observed in some studies. However, data for certain other groups are still emerging, and subgroup findings are uncertain because sample sizes were small.

---

Evidence Gaps and Areas of Uncertainty

The research provides context but not individual predictions, and several limitations must be acknowledged. First, the available research includes few head-to-head randomized controlled trials (RCTs) examining this specific three-component formulation. Second, the follow-up durations were limited, and long-term effects are not fully established. The results apply only to the populations studied, and data for certain comorbidity-defined groups are still emerging.

Key Studies & References Levosalbutamol, Ambroxol, and Guaiphenesin Syrup - Product Monograph (Ethiopian Food and Drug Authority, EFDA)

Common questions about Levolin PLUS (FAQ)

Q: What is the difference between Levolin PLUS and regular Levolin?

Regulatory documents state that Levolin PLUS is a fixed-dose combination drug. This means it contains Levosalbutamol, which is the active ingredient in regular Levolin, alongside two additional ingredients: Ambroxol and Guaifenesin. This combination is intended to address multiple aspects of respiratory distress simultaneously.

Q: Why is Levolin PLUS sometimes prescribed for breathing issues?

Official indications describe the drug's use for the symptomatic relief of conditions associated with reversible airway obstruction and a productive cough. The combination is specifically indicated for use when excessive or thickened mucus is also present.

Q: Does Levolin PLUS help with seasonal allergies?

The approved indications for this medication are focused on treating symptoms like bronchospasm (airway tightening) and mucus accumulation. Official regulatory labeling does not list conditions such as seasonal allergic rhinitis or related primary allergic symptoms as an approved use.

Q: What is the typical length of time the effects of Levolin PLUS are expected to last?

Based on the pharmacological properties of the bronchodilator component, the therapeutic effect is typically documented in official sources to last for approximately six to eight hours after administration. This aligns with the general recommendation for divided daily dosing.

Q: Do the side effects of Levolin PLUS usually lessen over time?

Official labeling documents note that certain common effects associated with the bronchodilator, such as tremor (shakiness) and nervousness, are known to diminish with the continued use of the therapy. Information regarding the duration of other common effects is not always detailed in official documents.

Q: What happens if a scheduled dose of Levolin PLUS is missed?

Regulatory-sourced patient information advises taking a missed dose as soon as it is remembered, unless the time is close to the next scheduled dose, in which case the missed dose should be skipped. Regulatory documents emphasize that the recommended dose limit must not be exceeded.

Q: What are the regulations surrounding the use of Levolin PLUS while breastfeeding?

Regulatory guidance advises against the use of this medicine during lactation (breastfeeding). This caution is based on the documentation that components of the drug, such as Levosalbutamol, may pass into breast milk.

Q: Is it considered normal to experience a slightly faster heart rate with Levolin PLUS?

Yes, official labeling documents classify an increased heart rate (tachycardia) and palpitations as common adverse reactions. These effects result from the activity of the bronchodilator component on the cardiovascular system.

Q: How do medical sources describe the risk of addiction or dependency with Levolin PLUS?

Regulatory medical documents do not associate this combination drug with a risk of addiction, dependency, or drug abuse potential. It is not generally classified as having a high risk for dependence.

Q: Is Levolin PLUS used for long-term or short-term treatment?

The medication is approved for the symptomatic relief of acute or exacerbating conditions. Therefore, it is generally intended for short-term use during periods of active symptoms. Use in continuous, long-term treatment is not typically within the scope of the approved indications.

Q: Can Levolin PLUS be taken at any time of day?

Regulatory documents specify that the syrup should be taken in divided doses throughout the day. It is also noted that the medication may be administered with or without food. The overall frequency of use is based on the dosing interval established by the healthcare provider.

Q: How quickly can someone expect Levolin PLUS to start working?

Official pharmacological information indicates that the onset of the bronchodilator effect from the Levosalbutamol component is rapid. This effect is typically documented to begin within 5 to 15 minutes after administration.

Q: Can Levolin PLUS be taken with common pain relievers like paracetamol?

Official interaction sections primarily list interactions with other prescription drug classes that share similar physiological effects. If a common non-prescription pain reliever like paracetamol is not explicitly listed, it suggests a clinically significant interaction is not documented in the product's official labeling.

Q: Is Levolin PLUS known to interact with caffeine?

Regulatory documents generally advise caution when combining this medicine with other sympathomimetic agents (stimulants). However, a specific interaction with caffeine is not explicitly listed in the official drug-drug interaction sections, which focus on pharmacological agents.

Q: Are there specific age groups where Levolin PLUS is not usually recommended?

Official labeling restricts the drug's use in children under two years of age due to insufficient data. Specific caution is also advised for use in the elderly population because of the increased cardiovascular risks associated with the bronchodilator component.

Q: What conditions might make a person ineligible to use Levolin PLUS?

Regulatory labeling lists several conditions that contraindicate the drug's use. These include known hypersensitivity to any component, pre-existing ischaemic heart disease, severe cardiac disease, gastric ulceration, and thyrotoxicosis.

Q: Has Levolin PLUS been studied for use in children under the age of six?

Clinical research evidence reported in regulatory documents indicates that studies for this combination have included observations within the pediatric population, including both infants and older children, even if use is restricted in the youngest groups.

Q: What general expectations should I have when starting Levolin PLUS?

The primary expected outcome noted in official documents is relief from difficulty breathing and clearing mucus. It is also noted that patients may commonly experience transient effects such as headache, tremor, and nervousness.

Q: How does the drug work to improve breathing, as described in official documents?

The official mechanism of action is threefold: it relaxes the muscles around the airways (bronchodilation), thins the mucus, and stimulates the overall clearance of secretions. This combined action is described as pharmacological synergy.

Q: Are there known interactions between Levolin PLUS and herbal supplements?

Official regulatory documents do not specifically list individual interactions with most herbal supplements. The interaction sections primarily cover established pharmacological agents and drug classes known to affect heart rate, blood pressure, or electrolyte levels.

Q: If the main issue seems resolved, can Levolin PLUS be discontinued?

As the drug is approved for the symptomatic relief of acute conditions, use is generally intended to be limited to the duration of active symptoms. The appropriate time for discontinuation is a decision determined by a healthcare provider.

Q: What are the signs that Levolin PLUS might not be suitable for someone?

Official warnings identify signs of potential intolerance, such as the immediate worsening of breathing difficulties, a condition known as paradoxical bronchospasm. The development of severe cardiovascular symptoms, such as severe palpitations or chest pain, is officially noted as requiring urgent medical consultation.

Q: What happens to the medicine in the body after it is taken (pharmacokinetics)?

Regulatory documents detail the pharmacokinetics, which describes how the components are processed by the body. This includes how the drug is absorbed, how it is metabolized (primarily in the liver), and how it is eventually excreted from the body (primarily through the kidneys).

Q: Do different formulations (like syrup vs. tablet) of Levolin PLUS have different effects?

Official regulatory documents provide pharmacokinetic and dynamic information that is specific to the approved oral solution/syrup formulation. Any other formulation, such as a tablet, would have its own specific regulatory labeling detailing its unique effects and absorption profile.

Q: Is the medication designed to prevent symptoms or treat existing ones?

The official indication is for the symptomatic treatment of acute respiratory conditions. This means the drug is designed to relieve existing symptoms of bronchospasm and cough rather than serving as a prophylactic (preventative) measure.

Q: What if Levolin PLUS does not seem to be working as expected?

Official warnings state that if symptoms worsen or if the drug appears less effective, this may be a sign of underlying disease progression. Regulatory advice mandates that this situation is officially noted as requiring medical consultation.

Q: Is Levolin PLUS related to albuterol or salbutamol?

The Levosalbutamol component is described in regulatory texts as the pharmacologically active L-isomer of the racemic compound known as Salbutamol (which is also called Albuterol). This means it is chemically related to the common bronchodilator.

Q: What information is available regarding research on different dosages of Levolin PLUS?

Clinical trial sections in regulatory documents report the specific doses that were utilized during the research studies that support the drug's approval. The evidence available applies only to the dose ranges that have been officially studied and approved.

How to Store and Dispose of Levolin PLUS

The storage of Levolin PLUS is strictly governed by regulatory requirements to ensure product stability. The medicine must be kept in a cool and dry place at a temperature below 30 C. It is mandatory to keep the product in its original container with the cap tightly closed and protect it from sunlight and moisture.

Child Safety and Disposal

For household safety, this medicine must always be stored out of the sight and reach of children and pets. Unused or expired medication must be disposed of properly. The official recommendation is to use a drug take-back program. If a take-back program is unavailable, mix the liquid with an undesirable substance, seal it in a container, and discard it in the household trash. Do not flush the medicine down the toilet.